Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma
A study for patients a with inoperable advanced bile duct cancer using photodynamic therapy (PDT)
Sponsor: Concordia Laboratories Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ8209
U.S. Govt. ID: NCT02082522
Contact: Francis Gress: 646-317-0492 / fgg2109@columbia.edu
Additional Study Information: The study aims to assess the effect of porfimer sodium with PDT administered with medical standard ofcare compared to medical standard of care alone on the overall survival time of patients with bile duct cancer and its effect on cholestasis (blocked bile flow), time-to-treatment failure, performance status, and health-related quality of life.
This study is closed
Investigator
Francis Gress, MD
Do You Qualify?
Have you been diagnosed with inoperable advanced bile duct cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Francis Gress
fgg2109@columbia.edu
646-317-0492
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE